An Assessment Of The Interchangeability Of Generic Metronidazole Tablets Under Bio- Waiver Conditions

Main Article Content

Olubukola O. Oyetunde
Moshood O. Akinleye
Ogochukwu Amaeze
Uche P. Ogbo


Background: Generic medicines significantly reduce cost of medicines to governments and individuals. They are more affordable than innovator medicines and thus improve availability of life savings medicines in many resource limited settings.

A number of generic metronidazole formulations are available for substitution in practice. However, the interchangeability of the different generic versions with one another or with the reference product is not common knowledge to health practitioners. This study assessed the interchangeability of innovator brand of metronidazole tablets (Flagyl®) with some generic metronidazole tablets using the biowaiver criteria.

Methods: Interchangeability of samples of metronidazole was assessed under biowaiver conditions, as approved for the industry by World Health Organization (WHO) and many regulatory bodies. Pharmacopeia methods were used to ascertain pharmaceutical equivalence. Dissolution profiles of metronidazole tablets at pH 1.2, 4.5 and 6.8 were compared using the similarity factor, to establish in vitro bioequivalence.

Results: The results showed that all metronidazole samples passed physicochemical assessments, while the innovator and five out of six generic samples passed the assay of drug content. All the brands of metronidazole assessed were rapidly dissolving (≥85% at 30 minutes) at pH 1.2 and pH 4.5 buffer but were not at pH 6.8 buffer. The dissolution profiles showed they were not superimposable.

None of the generics assessed have a similarity factor greater than 50 in the three media, meaning they are not equivalent to the innovator based on their dissolution profiles.

Conclusion: In vivo bioequivalence studies are required to ascertain therapeutic equivalence for these products. For Nigerian manufacturers to avail themselves of the cost saving effect of biowaivers, design and formulation of immediate release generic formulation must factor in appropriate excipients.

Article Details

How to Cite
O. Oyetunde, O. ., O. Akinleye, M. ., Amaeze, O. . ., & P. Ogbo, U. . (2017). An Assessment Of The Interchangeability Of Generic Metronidazole Tablets Under Bio- Waiver Conditions. The Nigerian Journal of Pharmacy, 51(1). Retrieved from
Author Biographies

Olubukola O. Oyetunde, Department of Clinical Pharmacy & Bio Pharmacy,

Faculty of Pharmacy, University of Lagos

Moshood O. Akinleye, Departmental of Pharmaceutical Chemistry,

Faculty of Pharmacy, University of Lagos

Ogochukwu Amaeze, Department of Clinical Pharmacy & Bio Pharmacy,

Faculty of Pharmacy, University of Lagos

Uche P. Ogbo, Department of Clinical Pharmacy & Bio Pharmacy,

Faculty of Pharmacy, University of Lagos


Gwaza L. (2016) Generic medicines. WHO Drug Inf. 30(3):370–5.

WHO. (2010) Improving access to essential medicines and creating efficiencies by encouraging the uptake of generic medicines. World Health Rep Heal System Finance Technical Brief Series 1:1–3.

WHO Expert committee on specification for pharmaceutical preparation (2006). Multisource (generic) pharmaceutical products : guidelines on registration requirements to establish. Vol. 937 Annex 7.

Davit BM, Kanfer I, Tsang YC, Cardot J. (2016). Mini-Review BCS Biowaivers : Similarities and Differences among EMA, FDA, and WHO Requirements. AAPS J. 18(3):612–8.

Oyetunde O, Aina B, Tayo F. (2014). Impact of generic substitution practice on care of diabetic patients. IJCP. 36(3):623–9.

Rediguieri CF, Porta V, Nunes DSG, Nunes TM, Junginger HE, Kopp S, et al. (2011) Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms : Metronidazole. J Pharm Sci. 100(5):1618–27.

British Pharmacopoeia (2012). Published by the Stationery office on behalf of the Medicines and Healthcare Products Regulatory Agency (MHRA) version 16.0;

United States Pharmacopoeia, USP 35 NF 30, (2012). The United States Pharmacopoeia Convention, Inc.

Bamiro OA, Odeniyi M, Osonuga O. (2007) Brand variations in the physicochemical properties of metronidazole tablets. Nig Q J Hosp Med. 17(1):22–5.

Ilomuanya MO, Mbaneme NA, Okubanjo OO, Ofokansi K. (2015). In vitro Equivalence Studies / Comparative Assessment of Generic Metronidazole Tablets Commercially Available in Lagos, Nigeria. Br J Pharm Res. 7(3):196–205.

Löbenberg R, Chacra NB, Stippler ES, Shah VP, Destefano AJ, Hauck WW, et al. (2012). Toward Global Standards for Comparator Pharmaceutical Products : Case Studies of Amoxicillin, Metronidazole, and Zidovudine in the Americas. AAPS J. 14(3):462–72.

Stuart AV, Zuo J, Löbenberg R. (2014). Investigating the Dissolution Profiles of Amoxicillin, Metronidazole, and Zidovudine Formulations used in Trinidad and Tobago, West Indies. AAPS Pharm. Sci. Tech. 15(5):1060–9.

Reddy NHS, Patnala S, Löbenberg R, Kanfer I. (2014). In Vitro Dissolution of Generic Immediate-Release Solid Oral Dosage Forms Containing BCS Class I Drugs : Comparative Assessment of Metronidazole, Zidovudine, and Amoxicillin Versus Relevant Comparator Pharmaceutical Products in South Africa and India. AAPS Pharm. Sci. Tech. 15(5):1076–86.

Akinleye M, Oyetunde O, Ayerota E, Okpara H. (2012). Equivalence of two generic brands of amlodipine besylate under biowaiver conditions. Int J Pharm Pharm Sci. 4:265–8.

Oyetunde OO, Tayo F, Akinleye MO, Aina BA. (2012). In Vitro Equivalence Studies of Generic Metformin Hydrochloride Tablets and Propranolol Hydrochloride Tablets under Biowaiver Conditions in Lagos State, Nigeria. Dissolution Technol. (November):51–5.